|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������� |
|
Ƥ���� |
|
��-�ڷ���-���ߵ��� |
| ��������������� | |
|
���� |
|
���긻 |
| PubMed | |
|
Article by |
|
Article by |
Ƥ������������������-�ڷ���-���ߵ���
����, ���긻
���пƼ���ѧͬ��ҽѧԺ����Э��ҽԺƤ���Բ���, �人430022
ijЩƤ���������ɾ��������շ�����ء���֪��-�ڷ���ϵͳ�ľ�ϸ�����ܱ�֤������ʹ���������߹���,һ�������������ʹ���������������ٴ�������ʾ�뾫��������ص�Ƥ�����������ڴ������߹���ʧ��,�Ʋ⾫�����ؿ���ͨ����-�ڷ���-����;�����յ�Ƥ�����ķ�����չ�����ľ;������ء�ijЩƤ���������ܴ��ڵ���-�ڷ���-���ߵ��ڻ�����һ������
[2] Raychaudhuri SP,Rein G,Fader EM.Neuropathogenesis and neurophar-macology of psoriasis.Int J Dermatol,1995,34(10):685-693.
[3] Farber EM,Rein G,Lanigan SW.Stress and psoriasis,psychoneuro-immunologic mechanisms.Int J Dermatol,1991,30(1):8-12.
[4] Jiang WY,Raychandhuri SP,Fader EM.Deuble-labeled immunofluo-rescence study of cutaneous nerves in psoriasis.Int J Dermatol,1998,37(8):572-574.
[5] Park YM,Kim CW.The effects of substance P and vasoactive intestinal peptide on interleukin-6 synthesis in cultured human keratinecytes.J Dermatol Sci,1999,22(1):17-23.
[6] Raychandhuri SK,Raychandhuri SP,Weltman H,et al.Effect of nerve growth factor on endothelial cell biology:proliferation and adherence molecule expression on human dermal microvascular endothelial cells.Arch Dermatol Res,2001,293(6):291-295.
[7] Staniek V,Doutremepuich J,Schmitt D,et al.Expression of substance P receptors in normal and psoriatic skin.Pathobiology,1999,67(1):51-54.
[8] Kakurai M,Fujita N,Murata S,et al.Vasoactive intestinal peptide regu-lates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal pepfide receptors.J Invest Dermatol,2001,116 (5):743-749.
[9] Bull HA,Leslie TA,Chepra S,et al.Expression of nerve growth factor receptors in cutaneous inflammation.Br J Dennatol,1998,139 (5):776-783.
[10] Giasuddin AS,El-Sherif AI,El-Ojali SI.Prolactin:does it have a role in the pathogenesis of psoriasis? Dermatology,1998,197(2):119-122.
[11] Lazarova R,Hristakieva E,Lazarov N,et al.Vitiligo-related neuropep-tides in nerve fibers of the skin.Arch Physiol Biechem,2000,108(3):262-267.
[12] Cucchi ML,Frattini P,Santagostino G,et al.Higher plasma cate-cholamine and metabolite levels in the early phase of nonsegmental vitili-go.Pigment Cell Res,2000,13(1):28-32.
[13] Mozzanica N,Villa ML,Foppa S,et al.Plasma alpha-melanecyte-stimu-lating hormone,beta-endorphin,metenkephalin,and natural killer cell activity in vitiligo.J Am Aead Dermatol,1992,26(5 Pt 1):693-700.
[14] Messenger AG.The control of hair growth:an overview.J Invest Dermatel,1993,101(1 Suppl):S4-S9.
[15] Rossi R,Del Biance E,Isolani D,et al.Possible involvement of neu-ropeptidergic sensory nerves in alepeeia areata.Neuroreport,1997,8(5):1135-1138.
[16] Toyeda M,Makino T,Kagonra M,et al.Expression of nem'epeptide-de-grading enzymes in alopecia areata:an immunohisteehemical study.Br J Dermatol,2001,144(1):46-54.
[17] Katsaron-Katsari A,Singh LK,Theoharides TC.Alepeeia areata and Affected Skin CRH Receptor Upregulafion Induced by Acute Emotional Stress.Dermatology,2001,203(2):157-161.
[18] Fenton DA,Tobin DJ,Kendall MD.Role of the thymus gland in alopecia areata.J Invest Dermatol,1995,104(5 Suppl):S25-S26.
[19] Howlett S.Emotional dysfunction,child-family relationships and child-hood atepic dermatitis.Br J Dermatol,1999,140(3):381-384.
[20] Linnet J,Jemec GB.An assessment of anxiety and dermatology life quality in patients with atepic dermatitis.Br J Dermatol,1999,140(2):268-272.
[21] Ward MM,Lotstein DS,Bush TM,et al.Psychosocial correlates of mor-bidity in women with systemic lupus erythematosus.J Rheumatol,1999,26(10):2153-2158.
[22] Da Costa D,Dobkin PL,Pinard L,et al.The role of stress in functional disability among women with systemic lupus erythematosus:a prospective study.Arthritis Care Res,1999,12 (2):112-9.
[23] Jacobi AM,Rehde W,Ventz M,et al.Enhanced senma prelactin (PRL) in patients with systemic lupus erythematosus:PRL levels are related to the disease activity.Lupus,2001,10(8):554-561.
[24] Revensky J,Jurankova E,Rauova L,et al.Relationship between en-deerine,immune,and clinical variables in patients with systemic lupus erythematosus.J Rheumatol,1997,24(12):2330-2334.
[25] Jacobi AM,Rohde W,Volk HD,et al,Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls.Ann Rheum Dis,2001,60(3):242-247.
[26] Bracci-Laudiero L,Aloe L,Lundeberg T,et al.Altered levels of neu-repeptides characterize the brain of lupus prone mice.Neurosci Lett,1999,275(1):57-60.
[27] Bracci-Laudiem L,Aloe L,Stenfors C,et al.Development of systemic lu-pus erythematosus in mice is associated with alteration of neuropeptide concentrations in inflamed kidneys and immunoregulatory organs.Neurosci Lett.1998.248(2):97-100.